Browse

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.

“Hospitals often make Argentina’s mistake: We confuse continuity with progress,” writes physician, hospital administrator, and bioethicist Basel Tarab.

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.